Based on the findings of this trial, the FDA approved pralsetinib for adult and pediatric patients with advanced or metastatic RET-fusion-positive lung and thyroid cancers for whom systemic therapy is indicated [120]. This evidence concerns the gene RET and thyroid gland carcinoma.